Aeterna Zentaris Inc.
AEZS
Κατάταξη σε μετοχές
#35356
Aeterna Zentaris Inc. operates as a specialized biopharmaceutical company,... Aeterna Zentaris Inc. operates as a specialized biopharmaceutical company, dedicated to the creation and market introduction of both therapeutic drugs and diagnostic tests. Its flagship product, macimorelin, is an orally administered peptidomimetic ghrelin receptor (GHSR-1a) agonist. This compound functions by binding to the GHSR-1a, thereby stimulating the secretion of growth hormone. Macimorelin is employed for diagnosing growth hormone deficiency in both adult and pediatric patients, and is also under investigation for various oncology indications. The drug is marketed commercially under the brand name Macrilen. The company engages in various licensing agreements, prominently with University Wuerzburg. This collaboration encompasses the research, development, manufacture, and commercialization of a prospective COVID-19 vaccine. It also involves developing, producing, and marketing a treatment for neuromyelitis optica spectrum disorder (NMOSD), establishing human 3D intestinal tissue models for infection biology research, and advancing pre-clinical work towards a potential Parkinson's disease therapy. Additionally, Aeterna Zentaris has formed licensing partnerships with Consilient Health Ltd., Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada. Another key collaboration is with The University of Sheffield in the United Kingdom, dedicated to the research, development, manufacturing, and commercialization of parathyroid hormone fusion polypeptides designed to treat primary hypoparathyroidism. Founded in 1990, Aeterna Zentaris Inc. maintains its corporate headquarters in Summerville, South Carolina.
Τιμή μετοχής
$3.97
Τελευταίος συγχρονισμός: 2024-09-03
Κεφαλαιοποίηση
$3.86M
Αλλαγή (1 ημέρα)
-1.00%
Αλλαγή (1 έτος)
-10.18%
Χώρα
US
Εμπόριο Aeterna Zentaris Inc. (AEZS)
Κατηγορία
Healthcare
Κεφαλαιοποίηση αγοράς του Aeterna Zentaris Inc.(AEZS)
Κεφαλαιοποίηση: $3.86M
Μέχρι το October 2026, η Aeterna Zentaris Inc. έχει χρηματιστηριακή αξία $3.86M. Αυτό καθιστά τη Aeterna Zentaris Inc. την 35356th πιο πολύτιμη εταιρεία στον κόσμο βάσει της κεφαλαιοποίησης σύμφωνα με τα δεδομένα μας. Η χρηματιστηριακή κεφαλαιοποίηση είναι η συνολική αγοραία αξία των μετοχών μιας εισηγμένης εταιρείας και χρησιμοποιείται συνήθως για να προσδιοριστεί η αξία μιας εταιρείας.
Ιστορικό κεφαλαιοποίησης αγοράς της Aeterna Zentaris Inc. από 2021 έως 2026
AEZS σε σύγκριση με τα 5 πιο δημοφιλή stocks
| Η τιμή για AEZS | Το περιουσιακό στοιχείο B | Η κεφαλαιοποίηση αγοράς του B | Αποτελέσματα | |
|---|---|---|---|---|
$66,511.36
$343.37M
|
$5.167T | +1,504,681.95% | ||
|
$64,551.42
$343.37M
|
$5.015T | +1,460,339.47% | ||
|
$52,884.33
$343.37M
|
$4.108T | +1,196,377.97% | ||
|
$50,226.23
$343.37M
|
$3.902T | +1,136,240.02% | ||
|
$34,619.31
$343.37M
|
$2.689T | +783,142.42% |
